N-Power Medicine Acquires Syapse
December 30, 2024
N-Power Medicine completed a stock-for-stock acquisition of Syapse on December 30, 2024, integrating Syapse’s precision-medicine technology, data assets and network of community oncologists into N-Power’s Kaleido Registry and AI-enabled point-of-care platform. Innovatus Capital Partners joined N-Power’s existing investors (including the Merck Global Health Innovation Fund) to provide ongoing funding; Canaccord Genuity served as Syapse’s exclusive financial advisor.
- Buyers
- N-Power Medicine
- Targets
- Syapse
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Syros Pharmaceuticals Merges with TYME Technologies
September 16, 2022
Biotechnology
Syros Pharmaceuticals completed a merger with TYME Technologies, acquiring TYME's pipeline assets and approximately $60 million of net cash at closing. The transaction was accompanied by an oversubscribed $130 million PIPE financing to provide capital for Syros' late-stage hematology programs and early commercialization activities.
-
AbbVie Acquires Syndesi Therapeutics
March 1, 2022
Biotechnology
AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.
-
Softheon Acquires NextHealth Technologies
June 30, 2022
Healthcare Services
Softheon has acquired NextHealth Technologies, an AI-powered SaaS healthcare analytics platform, to accelerate its AI and care-management capabilities for health plans. The deal brings NextHealth’s team and technology into Softheon and results in NextHealth investors Norwest Venture Partners and TT Capital Partners becoming investors in Softheon to support combined growth.
-
NLS Pharmaceutics Merges with Kadimastem to Form NewCelX
June 27, 2025
Biotechnology
NLS Pharmaceutics Ltd. completed a $3.0 million equity financing to support its pending merger with Kadimastem Ltd.; the transaction closed and the combined company was re-named NewCelX Ltd. The deal brings together NLS's CNS-focused pipeline and Kadimastem's cell therapy programs (AstroRx and IsletRx) to advance clinical development for ALS, diabetes and other regenerative-medicine indications.
-
Riverside Partners Combines Sequoia Biotech Consulting and Syner-G BioPharma Group
September 18, 2024
Healthcare Services
Boston-based private equity firm Riverside Partners has combined two of its portfolio companies, Sequoia Biotech Consulting and Syner-G BioPharma Group, into a single, integrated life‑sciences services business. The combined organization — bringing together regulatory, development, quality, and operational capabilities — has approximately 500 employees and will provide end-to-end solutions to pharmaceutical, biotechnology, and medical device clients.
-
Kyruus Acquires HealthSparq
February 3, 2022
Healthcare Services
Kyruus, a Boston-based provider search and scheduling platform, completed the acquisition of HealthSparq, a Portland-based healthcare guidance and transparency vendor. The deal brings payer-focused price-transparency and guidance capabilities into Kyruus’s provider access platform to connect payers, providers, and consumers and expand the company’s market reach.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.